

**TRANSMITTAL OF INFORMATION DISCLOSURE STATEMENT**  
(Under 37 CFR 1.97(b) or 1.97(c))

Docket No.  
WINTE-045244

In Re Application of **WOLFGANG WUTTE, et al.**

**RECEIVED**

Serial No.  
09/646,740

DEC 20 2000

Filing Date  
September 18, 2000

Examiner  
Unassigned

Group Art Unit  
1614

TECH CENTER 1600/2800

Title: **UTILIZATION OF EXTRACTS FROM IRIS PLANTS, CIMCIFUGA RACEMOSA AND TECTORIGENIN AS AN ESTROGEN-LIKE ORGAN-SELECTIVE MEDICAMENT WITHOUT UTEROTROPIC EFFECTS**

Address to:  
Assistant Commissioner for Patents  
Washington, D.C. 20231

**37 CFR 1.97(b)**

1. ☒ The Information Disclosure Statement submitted herewith is being filed within three months of the filing of a national application; within three months of the date of entry of the national stage as set forth in 37 CFR 1.491 in an international application; or before the mailing date of a first Office Action on the merits, whichever event occurs last.

**37 CFR 1.97(c)**

2. ☐ The Information Disclosure Statement submitted herewith is being filed after three months of the filing of a national application, or the date of entry of the national stage as set forth in 37 CFR 1.491 in an international application; or after the mailing date of a first Office Action on the merits, whichever occurred last but before the mailing date of either:

1. a Final Action under 37 CFR 1.113, or
2. a Notice of Allowance under 37 CFR 1.311,

whichever occurs first.

Also submitted herewith is:

- ☐ a certification as specified in 37 CFR 1.97(e);

**OR**

- ☐ the fee set forth in 37 CFR 1.17(p) for submission of an Information Disclosure Statement under 37 CFR 1.97(c).

**TRANSMITTAL OF INFORMATION DISCLOSURE STATEMENT**  
(Under 37 CFR 1.97(b) or 1.97(c))

Docket No.  
WINTE-045244

In Re Application Of: **WOLFGANG WUTTE, et al.**

**RECEIVED**

Serial No.  
09/646,740

Filing Date  
September 18, 2000

Examiner  
Unassigned

DEC 26 2000  
Group Art Unit  
1614

Title: **UTILIZATION OF EXTRACTS FROM IRIS PLANTS, CIMCIFUGA RACEMOSA AND TECTORIGENIN AS AN ESTROGEN-LIKE ORGAN-SELECTIVE MEDICAMENT WITHOUT UTEROTROPIC EFFECTS**

**Payment of Fee**

(Only complete if Applicant elects to pay the fee set forth in 37 CFR 1.17(p))

- ☐ A check in the amount of \_\_\_\_\_ is attached.
- ☒ The Assistant Commissioner is hereby authorized to charge and credit Deposit Account No. 16-2460 as described below. A duplicate copy of this sheet is enclosed.
- ☐ Charge the amount of \_\_\_\_\_
- ☒ Credit any overpayment.
- ☒ Charge any additional fee required.

**Certificate of Transmission by Facsimile\***

I certify that this document and authorization to charge deposit account is being facsimile transmitted to the United States Patent and Trademark Office (Fax. No. \_\_\_\_\_)

on \_\_\_\_\_  
(Date)

Signature

Typed or Printed Name of Person Signing Certificate

**Certificate of Mailing by First Class Mail**

I certify that this document and fee is being deposited on 12/14/00 with the U.S. Postal Service as first class mail under 37 C.F.R. 1.8 and is addressed to the Assistant Commissioner for Patents, Washington, D.C. 20231.

*Karen A. Wuerfel*  
Signature of Person Mailing Correspondence

Karen Wuerfel

Typed or Printed Name of Person Mailing Correspondence

\*This certificate may only be used if paying by deposit account.

*Laurence H. Pretty*  
Signature

Dated: 12/14/00

Laurence H. Pretty, Esq.  
Registration No. 25,312  
PRETTY & SCHROEDER, P.C.  
444 South Flower Street  
19th Floor  
Los Angeles, CA 90071  
(213) 622-7700

CC:



RECEIVED  
WINTe-045244

DEC 26 2000

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

TECH CENTER 1600/2900

In re application of: )  
 )  
Wolfgang Wutte, et al. )  
 )  
Serial No.: 09/646,740 )  
 )  
Filing Date: September 18, 2000 )  
 )  
Title: Utilization of Extracts From )  
Iris Plants, Cimicifuga Racemosa )  
and Tectorigenin as an Estrogen- )  
Like Organ-Selective Medicament )  
Without Uterotropic Effects )  
 )

Examiner: Unassigned

Art Unit No.: 1614

INFORMATION DISCLOSURE STATEMENT

Assistant Commissioner for  
Patents  
Washington, D. C. 20231

I HEREBY CERTIFY THAT THIS CORRESPONDENCE IS BEING DEPOSITED WITH THE UNITED STATES POSTAL SERVICE AS FIRST CLASS MAIL IN AN ENVELOPE ADDRESSED TO THE ASSISTANT COMMISSIONER FOR PATENTS WASHINGTON, D.C. 20231, ON 12/14/00	
BY <u>Karen Wuertel</u>	DATE
12/14/00	(DATE OF SIGNATURE)

Dear Sir:

Applicants' attorney submits herewith the International Search Report for the corresponding PCT application and full text literature cited therein that he believes may be material to the examination of this application and in respect of which there may be a duty to disclose in accordance with 37 CFR 1.56.

Each item of information contained in the accompanying information disclosure statement was cited in a communication from a foreign patent office

(Europatent Office) in a counterpart foreign application not more than three months prior to the filing of the information disclosure statement.


The filing of this information disclosure statement shall not be construed as a representation that a search has been made (37 CFR 1.97(g)), an admission that the information cited is, or is considered to be, material to patentability or that no other material information exists (37 CFR 1.97(h)). Further, the filing of this information disclosure statement shall not be construed as an admission against interest in any manner.

The information disclosure statement submitted herewith is being filed within three months of the filing of a national application; within three months of the date of entry of the national stage as set forth in 37 CFR 1.491 in an international application; or before the mailing date of a first Office Action on the merits, whichever event occurs last.

Respectfully submitted,

PRETTY & SCHROEDER, P.C.

Date: 12-14-01

By:   
Laurence H. Pretty  
Registration No. 25,312

444 South Flower Street -19<sup>th</sup> Floor  
Los Angeles, California 90071  
(213) 622-7700  
31806.1